Abstracts tagged "cyclophosphamide and systemic lupus erythematosus (SLE)"

Abstract Number: 1640 • 2014 ACR/ARHP Annual Meeting
Cyclophosphamide Diminishes Plasmablasts and Transitional B Cells and Suppresses Autocrine Production of B Cell Activating Factor of Tumor Necrosis Factor Family (BAFF) in These Cells in Patients with Systemic Lupus Erythematosus
Yuko Okamoto¹, Yasuhiro Katsumata¹, Yasushi Kawaguchi¹, Manabu Kawamoto¹, Takahisa Gono¹, Masanori Hanaoka¹, Tomoaki Higuchi¹, Hidenaga Kawasumi¹ and Hisashi Yamanaka², ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose . B cell activating factor of tumor necrosis factor family (BAFF) is a positive regulator of B cell function and expressed in dendritic cells,…
Abstract Number: 1639 • 2014 ACR/ARHP Annual Meeting
Serum Anti-Müllerian Hormone Levels in SLE Patients. the Disease Severity and Cyclophosphamide Reduce the Ovarian Reserve
Gerardo Marino¹, Laura Messuti¹, Maria Rita Gigante¹, Angela Barini², Silvia Canestri¹, Antonella Barini², Barbara Tolusso¹, Elisa Gremese¹ and Gianfranco Ferraccioli¹, ¹Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy, ²Department of Laboratory Medicine, Institute of Biochemistry and Clinical Biochemistry, Catholic University of The Sacred Heart, Rome, Italy
Background/Purpose . Systemic lupus erythematosus (SLE) predominantly affects women of childbearing age, can lead to severe organ involvement and may require prolonged immunosuppressive therapy. Anti-Müllerian Hormone is produced by the granulosa ovary cells and…

All abstracts accepted to ACR Convergence are under embargo once the ACR has notified presenters of their abstract’s acceptance, and cannot be presented at other meetings after this time. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until November 7 at 10:00 AM ET. Journalists with access to embargoed information also cannot release articles before this time.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Permissions and Reprints

For information about abstract permissions and reprints, see ACR Convergence permissions and reprint policies.